Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma

被引:1
作者
Moreno, Victor Navas [1 ,2 ]
Valles, Fernando Sebastian [1 ,2 ]
Vargas, Marcos Lahera [1 ,2 ]
Marin, Berta Hernandez [2 ,3 ,4 ]
Lopez, Elena Carrillo [1 ]
Marazuela, Monica [1 ,2 ,3 ]
de Nova, Jose Luis Munoz [2 ,4 ,5 ]
机构
[1] Hosp Univ Princesa, Dept Endocrinol & Nutr, Madrid 28028, Spain
[2] Inst Invest Sanitaria Princesa IIS IP, Madrid 28028, Spain
[3] Hosp Univ Princesa, Dept Oncol, Madrid 28028, Spain
[4] Hosp Univ Princesa, Dept Gen & Digest Surg, Madrid 28028, Spain
[5] Univ Autonoma Madrid, Dept Surg, Madrid 28029, Spain
关键词
thyroid cancer; neoadjuvant treatment; targeted therapies; advanced thyroid cancer; thyroidectomy; DOXORUBICIN PLUS CISPLATIN; DOUBLE-BLIND; ASSOCIATION GUIDELINES; CANCER; CHEMOTHERAPY; THERAPY; MANAGEMENT; MEDULLARY; LENVATINIB; BRAF;
D O I
10.3390/jcm13195769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the focus in the last decades has been on the overdiagnosis of incidentally detected thyroid carcinomas in early stages, the other extreme of the disease is represented by locally advanced tumors with the invasion of neighboring structures. These are infrequent tumors, but they have a high complexity and a poor prognosis. In the absence of effective therapies allowing preoperative tumor reduction, in order to achieve a more restricted surgery, treatment was limited to aggressive surgery with resection of the aerodigestive tract and major vascular structures or palliative treatment. However, due to the increased knowledge of tumor biology and the results that tyrosine kinase inhibitors have achieved in the treatment of radioactive iodine-refractory tumors, neoadjuvant therapy with a curative intent has emerged as a reality to be taken into account when dealing with these patients. This paper presents a narrative review of the current scientific evidence regarding neoadjuvant treatment in locally advanced thyroid cancer.
引用
收藏
页数:12
相关论文
共 92 条
  • [1] Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992-2006
    Aschebrook-Kilfoy, Briseis
    Ward, Mary H.
    Sabra, Mona M.
    Devesa, Susan S.
    [J]. THYROID, 2011, 21 (02) : 125 - 134
  • [2] Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report
    Barbaro, Daniele
    Forleo, Raffaella
    Profilo, Maria Antonietta
    Lapi, Paola
    Giani, Carlotta
    Torregrossa, Liborio
    Macerola, Elisabetta
    Materazzi, Gabriele
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [3] Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
    Barbaro, Daniele
    Lapi, Paola
    Viacava, Paolo
    Torregrossa, Liborio
    [J]. BMJ CASE REPORTS, 2020, 13 (12)
  • [4] Neoadjuvant Chemotherapy in 16 Patients with Locally Advanced Papillary Thyroid Carcinoma
    Besic, Nikola
    Auersperg, Marija
    Dremelj, Marta
    Vidergar-Kralj, Barbara
    Gazic, Barbara
    [J]. THYROID, 2013, 23 (02) : 178 - 184
  • [5] Neoadjuvant Chemotherapy in 29 Patients with Locally Advanced Follicular or Hurthle Cell Thyroid Carcinoma: A Phase 2 Study
    Besic, Nikola
    Auersperg, Marija
    Gazic, Barbara
    Dremelj, Marta
    Zagar, Ivana
    [J]. THYROID, 2012, 22 (02) : 131 - 137
  • [6] 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force
    Bible, Keith C.
    Kebebew, Electron
    Brierley, James
    Brito, Juan P.
    Cabanillas, Maria E.
    Clark, Thomas J., Jr.
    Di Cristofano, Antonio
    Foote, Robert
    Giordano, Thomas
    Kasperbauer, Jan
    Newbold, Kate
    Nikiforov, Yuri E.
    Randolph, Gregory
    Rosenthal, M. Sara
    Sawka, Anna M.
    Shah, Manisha
    Shaha, Ashok
    Smallridge, Robert
    Wong-Clark, Carol K.
    [J]. THYROID, 2021, 31 (03) : 337 - 386
  • [7] Thyroid Cancer
    Boucai, Laura
    Zafereo, Mark
    Cabanillas, Maria E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (05): : 425 - 435
  • [8] Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
    Brose, Marcia S.
    Robinson, Bruce
    Sherman, Steven, I
    Krajewska, Jolanta
    Lin, Chia-Chi
    Vaisman, Fernanda
    Hoff, Ana
    Hitre, Erika
    Bowles, Daniel W.
    Hernando, Jorge
    Faoro, Leonardo
    Banerjee, Kamalika
    Oliver, Jennifer W.
    Keam, Bhumsuk
    Capdevila, Jaume
    [J]. LANCET ONCOLOGY, 2021, 22 (08) : 1126 - 1138
  • [9] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    [J]. LANCET, 2014, 384 (9940) : 319 - 328
  • [10] Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma
    Cabanillas, Maria E.
    Ferrarotto, Renata
    Garden, Adam S.
    Ahmed, Salmaan
    Busaidy, Naifa L.
    Dadu, Ramona
    Williams, Michelle D.
    Skinner, Heath
    Gunn, G. Brandon
    Grosu, Horiana
    Iyer, Priyanka
    Hofmann, Marie Claude
    Zafereo, Mark
    [J]. THYROID, 2018, 28 (07) : 945 - 951